DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01345734

Lead-Ph

Completed

Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes

Liraglutide Effectiveness and Safety Data From Routine Clinical Practice in Philippines Study. A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes Mellitus in Philippines

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

1,056

actual

Study population

Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Serious AEs (any)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01345734
Org study IDNN2211-3932
Secondary IDU1111-1119-8803WHO

Timeline

Milestones

Study first posted2011-05-02estimated
Study start2011-09-01actual
Primary completion2013-07-26actual
Study completion2013-07-26actual
Last update posted2018-12-11actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Adult subjects with type 2 diabetes, including newly-diagnosed subjects or those already receiving other anti-diabetic medications including GLP-1 analogues other than liraglutide.

Inclusion criteria

•Subjects with type 2 diabetes mellitus, including newly-diagnosed subjects or those already receiving other anti-diabetic medications including GLP-1 analogues other than Liraglutide, who require treatment with liraglutide according to the clinical judgment of their treating physician
•Subjects who are capable of giving study-specific signed informed consent before any collection of information

Exclusion criteria

•Subjects with type 1 diabetes
•Subjects who are or have previously been on liraglutide
•Subjects who are participating in another clinical trial
•Subjects with a hypersensitivity to liraglutide or to any of the excipients (Disodium phosphate dihydrate, propylene glycol, phenol, water for injections)
•Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the following 6 months

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
4
Glycemic / diabetes
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change in HbA1c (glycosylated haemoglobin)"

Time frame:Week 0, week 26

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Safety / tolerability / PK

4 endpoints
Primary/protocol endpoint

Incidence of serious adverse drug reactions (SADRs)

Time frame:Week 0, week 26

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Incidence of adverse drug reactions (ADRs)

Time frame:Week 0, week 26

event count, event

Secondary/protocol endpoint

Incidence of serious adverse events (SAEs)

Time frame:Week 0, week 26

Serious AEs (any)

event count, event

Secondary/protocol endpoint

Frequency of hypoglycaemic episodes

Time frame:Week 0, week 26

Documented hypoglycemia

event count, event

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.